2020
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, Denkert C, Ellis MJ, Fineberg S, Flowers M, Kreipe HH, Laenkholm AV, Pan H, Penault-Llorca FM, Polley MY, Salgado R, Smith IE, Sugie T, Bartlett JMS, McShane LM, Dowsett M, Hayes DF. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. Journal Of The National Cancer Institute 2020, 113: 808-819. PMID: 33369635, PMCID: PMC8487652, DOI: 10.1093/jnci/djaa201.Peer-Reviewed Original ResearchConceptsBreast cancerClinical utilityKi67 immunohistochemistryInternational Ki67Breast Cancer Working GroupAnalytical validityAssessment of Ki67HER2-negative patientsBreast cancer careCancer Working GroupGroup consensus meetingAdjuvant chemotherapyVisual scoring methodPatient groupCancer careT1-2Prognostic markerPrognosis assessmentPrognosis estimationTreatment decisionsEstrogen receptorHER2 testingConsensus meetingCurrent evidenceClinical validity
2016
EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma
Toki MI, Carvajal-Hausdorf DE, Altan M, McLaughlin J, Henick B, Schalper KA, Syrigos KN, Rimm DL. EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma. Journal Of Thoracic Oncology 2016, 11: 1901-1911. PMID: 27449805, PMCID: PMC5075503, DOI: 10.1016/j.jtho.2016.06.025.Peer-Reviewed Original ResearchConceptsEGFR pathway activationSeries of patientsLung adenocarcinomaMutation statusEGFR expressionPathway activationProximity ligation assayKRAS wild-type tumorsEGFR-mutant patientsKRAS-mutant casesCohort of patientsWild-type tumorsInteraction of EGFREGFR expression levelsEGFR protein expressionMAPK/ERK pathwayGrowth factor receptorActive EGFRPrognostic factorsDifferent mutation statusPatient groupPrognostic valueLonger survivalEGFR mutationsPrognostic marker
2004
Increased Tissue Microarray Matrix Metalloproteinase Expression Favors Proteolysis in Thoracic Aortic Aneurysms and Dissections
Koullias GJ, Ravichandran P, Korkolis DP, Rimm DL, Elefteriades JA. Increased Tissue Microarray Matrix Metalloproteinase Expression Favors Proteolysis in Thoracic Aortic Aneurysms and Dissections. The Annals Of Thoracic Surgery 2004, 78: 2106-2110. PMID: 15561045, DOI: 10.1016/j.athoracsur.2004.05.088.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAorta, ThoracicAortic Aneurysm, ThoracicAortic DissectionFemaleHumansMaleMatrix Metalloproteinase 1Matrix Metalloproteinase 2Matrix Metalloproteinase 9Matrix MetalloproteinasesTissue Array AnalysisTissue Inhibitor of Metalloproteinase-1Tissue Inhibitor of Metalloproteinase-2ConceptsAortic dissection patientsHigher MMP-2Thoracic aortic aneurysmAortic aneurysmMMP-9MMP-2Dissection patientsThoracic aneurysmMMP-1Matrix metalloproteinasesControl aortic specimensAortic aneurysm patientsTIMP-1 ratioEntire patient groupImportant pathophysiologic roleMMP-9 expressionMatrix metalloproteinase expressionAreas of diseaseControl patientsAortic dissectionControl specimensPathophysiologic mechanismsAortic diseasePatient groupAneurysm patients